Biopharma AI and API Markets Project Strong Growth to 2030

Market research forecasts indicate rapid expansion in two pharmaceutical sectors. The global artificial‑intelligence market for biopharma is projected to grow from $2.79 billion in 2026 to $8.78 billion by 2030, a compound annual growth rate (CAGR) of 33.1 %. Growth drivers include wider adoption of machine‑learning and deep‑learning tools, increased investment in precision medicine, cloud‑based platforms, and strategic partnerships between AI firms and drug developers.

The active pharmaceutical ingredient (API) market is expected to rise from $260.71 billion in 2026 to $341.32 billion in 2030, a 7.0 % CAGR. Demand is fueled by the rising prevalence of chronic diseases, expansion of biopharma and peptide‑based therapies, and the use of AI‑enabled drug discovery to accelerate development. Companies are investing in advanced manufacturing technologies, expanding contract‑manufacturing capacity, and pursuing acquisitions to strengthen global supply chains. Both forecasts reflect broader trends toward AI integration and personalized treatment in the pharmaceutical industry.